Orchard Therapeutics Stock Forecast, Price & News

+0.04 (+0.78 %)
(As of 06/14/2021 01:15 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume13,956 shs
Average Volume342,051 shs
Market Capitalization$638.65 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ORTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Orchard Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Orchard Therapeutics logo

About Orchard Therapeutics

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.45 out of 5 stars

Medical Sector

650th out of 2,099 stocks

Biological Products, Except Diagnostic Industry

83rd out of 198 stocks

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Orchard Therapeutics (NASDAQ:ORTX) Frequently Asked Questions

Is Orchard Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Orchard Therapeutics stock.
View analyst ratings for Orchard Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Orchard Therapeutics?

Wall Street analysts have given Orchard Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Orchard Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Orchard Therapeutics' next earnings date?

Orchard Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Orchard Therapeutics

How were Orchard Therapeutics' earnings last quarter?

Orchard Therapeutics plc (NASDAQ:ORTX) announced its quarterly earnings data on Thursday, May, 13th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.02.
View Orchard Therapeutics' earnings history

How has Orchard Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Orchard Therapeutics' stock was trading at $9.08 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ORTX shares have decreased by 43.1% and is now trading at $5.17.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ORTX?

4 brokers have issued 12-month price objectives for Orchard Therapeutics' stock. Their forecasts range from $12.00 to $17.00. On average, they expect Orchard Therapeutics' share price to reach $15.00 in the next twelve months. This suggests a possible upside of 190.1% from the stock's current price.
View analysts' price targets for Orchard Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Orchard Therapeutics' key executives?

Orchard Therapeutics' management team includes the following people:
  • Dr. Bobby Gaspar Ph.D., M.D., CEO, Member of Scientific Advisory Board & Exec. Director (Age 56, Pay $519.47k)
  • Mr. Frank E. Thomas, Pres & COO (Age 51, Pay $691.24k)
  • Ms. Renee T. Leck, Director of Investor Relations
  • Mr. John Ilett, Chief of Staff, Chief Legal Officer & Company Sec.
  • Molly Cameron, Mang. of Corp. Communications
  • Mr. John Cerio, Chief Human Resource Officer
  • Dr. Anne Dupraz-Poiseau, Chief Devel. Officer
  • Mr. Adrien Lemoine, Chief Bus. Officer
  • Mr. Robin Kenselaar, Sr. VP & GM of EMEA Commercial Operations
  • Mr. Braden Parker, Chief Commercial Officer

Who are some of Orchard Therapeutics' key competitors?

What other stocks do shareholders of Orchard Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Orchard Therapeutics investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), Entasis Therapeutics (ETTX), (NGM), Selecta Biosciences (SELB) and VBI Vaccines (VBIV).

When did Orchard Therapeutics IPO?

(ORTX) raised $200 million in an initial public offering on Wednesday, October 31st 2018. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Orchard Therapeutics' stock symbol?

Orchard Therapeutics trades on the NASDAQ under the ticker symbol "ORTX."

Who are Orchard Therapeutics' major shareholders?

Orchard Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Artisan Partners Limited Partnership (8.60%), JPMorgan Chase & Co. (3.84%), Lord Abbett & CO. LLC (1.43%), Sphera Funds Management LTD. (1.13%), New York State Common Retirement Fund (1.05%) and Baker BROS. Advisors LP (0.61%).
View institutional ownership trends for Orchard Therapeutics

Which major investors are selling Orchard Therapeutics stock?

ORTX stock was sold by a variety of institutional investors in the last quarter, including Woodline Partners LP, Morgan Stanley, Goldman Sachs Group Inc., Platinum Investment Management Ltd., Forefront Analytics LLC, Mutual of America Capital Management LLC, Squarepoint Ops LLC, and Ameriprise Financial Inc..
View insider buying and selling activity for Orchard Therapeutics
or view top insider-selling stocks.

Which major investors are buying Orchard Therapeutics stock?

ORTX stock was purchased by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Lord Abbett & CO. LLC, Sphera Funds Management LTD., JPMorgan Chase & Co., New York State Common Retirement Fund, Rafferty Asset Management LLC, Baker BROS. Advisors LP, and GSA Capital Partners LLP.
View insider buying and selling activity for Orchard Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Orchard Therapeutics?

Shares of ORTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Orchard Therapeutics' stock price today?

One share of ORTX stock can currently be purchased for approximately $5.17.

How much money does Orchard Therapeutics make?

Orchard Therapeutics has a market capitalization of $639.89 million and generates $2.60 million in revenue each year. The company earns $-151,980,000.00 in net income (profit) each year or ($1.53) on an earnings per share basis.

How many employees does Orchard Therapeutics have?

Orchard Therapeutics employs 224 workers across the globe.

What is Orchard Therapeutics' official website?

The official website for Orchard Therapeutics is

Where are Orchard Therapeutics' headquarters?

Orchard Therapeutics is headquartered at 108 CANNON STREET, LONDON X0, EC4N 6EU.

How can I contact Orchard Therapeutics?

Orchard Therapeutics' mailing address is 108 CANNON STREET, LONDON X0, EC4N 6EU. The company can be reached via phone at 011-44-0-203-3846700.

This page was last updated on 6/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.